Novartis reported a 14% increase in group sales in the second quarter on the strength of its innovative medicines division and a rebound at the Sandoz generics unit. Sandoz had experienced weak retail demand and price competition at the start of the year, but the business was starting to stabilise as the second quarter drew to a close, the company said in its half-year review on 21 July.
